

Pfizer Inc.
235 East 42nd Street
New York, NY 10017



February 26, 2015

Re: **IMPORTANT PRODUCT SUPPLY INFORMATION**

**Antivenin (*Micrurus fulvius*)
North American Coral Snake Antivenin (Equine Origin)**

**FURTHER EXTENSION OF EXPIRATION DATING TO APRIL 30, 2016
LOT NO. 4030024**

Dear Health Care Provider:

Wyeth Pharmaceuticals (a subsidiary of Pfizer Inc.) would like to provide you with updated and very important information regarding Antivenin (*Micrurus fulvius*) North American Coral Snake Antivenin (Equine Origin).

As you may know, Wyeth Pharmaceuticals no longer manufactures Antivenin, and there is currently no alternative FDA-approved supplier of this product.

Last April, Wyeth Pharmaceuticals announced the extension of the expiration date of Lot No. 4030024 to April 2015. Due to limited supply of Antivenin, Wyeth Pharmaceuticals, working closely with the U.S. Food and Drug Administration (FDA), is extending the expiration date of **Antivenin, Lot No. 4030024, to April 30, 2016**. Wyeth Pharmaceuticals has stability data that indicate product from Lot No. 4030024 continues to be within applicable specifications.

Pfizer is carefully managing Antivenin inventories and will supply product only to direct customers.


Antivenin is indicated for the treatment of envenomation caused by the bites of *M. f. fulvius* (eastern coral snake) and *M. f. tenere* (Texas coral snake).

Patients sensitive to Antivenin or horse serum may develop anaphylaxis. Therefore, it is essential that prior to intravenous or intramuscular Antivenin administration a proper skin test be performed, interpreted, and therapy modified if indicated. Since the possibility of a severe immediate reaction (anaphylaxis) always exists whenever horse serum is administered appropriate therapeutic agents, such as tourniquet, oxygen supply, epinephrine 1:1000, and another injectable pressor amine (not corticosteroids) must be ready for immediate use.

Please see accompanying full Prescribing Information for indications and usage, dosage and administration, and important safety information. Also, the product Prescribing Information can be accessed at www.pfizer.com.

If you have any questions, please call our Customer Service Department at 1-800-666-7248.

Sincerely,



Salomon Azoulay, M.D.
Senior Vice President
Global Established Pharma
Global Clinical and Medical Affairs
Pfizer Inc.